Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
US OptionsDetailed Quotes
SMMT250425P40000
- 14.30
- 0.000.00%
15min DelayClose Apr 25 16:00 ET
0.00High0.00Low
0.00Open14.30Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover0.00%IV7.89%PremiumApr 25, 2025Expiry Date12.10Intrinsic Value100Multiplier-7DDays to Expiry2.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.95Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Newsroom
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics Analyst Ratings
Goldman Sachs Maintains Buy on Summit Therapeutics, Raises Price Target to $41
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $30 to $44
Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)
Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities
Truist Financial Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $44
Summit Therapeutics Is Maintained at Buy by Jefferies
Summit Therapeutics Price Target Raised to $44.00/Share From $31.00 by Jefferies
Summit Therapeutics Analyst Ratings
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Summit Therapeutics Analyst Ratings
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
BRK cash at new high: What to expect from Buffett’s meeting?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now